Heart and Vessels

, Volume 5, Issue 4, pp 224–229 | Cite as

In vivo31P nuclear magnetic resonance findings on heterotopically allografted hearts in rats treated with a novel immunosuppressant, FK 506

  • Seiichi Suzuki
  • Masaru Kanashiro
  • Ryosuke Hayashi
  • Takashi Kenmochi
  • Toshiyuki Fukuoka
  • Hiroshi Amemiya
Originals

Summary

Administration of FK506 for 15 days at daily doses of 3.2 mg/kg p.o., 10 mg/kg p.o., 0.32 mg/kg i.m., or 1 mg/kg i.m. to heart-allografted rats resulted in a significant prolongation of graft survival time. The best graft acceptance was obtained in the 1 mg/kg i.m. group: all six grafts survived longer than 50 days, and two of them, indefinitely. The31P nuclear magnetic resonance (NMR) technique was utilized to investigate in vivo the energy metabolism of grafts. The ratios of inorganic phosphate (Pi)/phosphocreatine (PCr) and PCr/ATP were useful parameters for monitoring cardiac insufficiency after transplantation. The mean ratios of Pi/PCr and PCr/ATP in syngeneic grafts were 0.38±0.11 and 1.88±0.42, respectively. In the control allografts, a rapid increase in the Pi/PCr ratio and a decrease in the PCr/ATP ratio were found from day 5. During the period of FK 506 administration, increased Pi/PCr and decreased PCr/ATP ratios were also observed in all groups. The changes in these ratios were related with FK506 dosage. The results suggest that FK506 has a side-effect on graft metabolism. The metabolism tended to improve upon cessation of the drug in all grafts, but it worsened again in 3–3 1/2 weeks in the rats treated with 3.2 mg/kg p.o., 10 mg/kg p.o., or 0.32 mg/kg i.m. This seemed to be due to graft rejection. In the 1 mg/kg i.m. group, lowering of the Pi/PCr ratio and elevation of the PCr/ATP ratio were observed after the withdrawal of FK506, and these ratios remained stable until the end of the observation period. In conclusion, FK506 was found to be a potent immunosuppressant with a significant side-effect on graft metabolism.

Key words

31P-NMR Heart transplantation Rejection FK506 Rat 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Suzuki S, Kanashiro M, Amemiya H (1987) Effect of a new immunosuppressant, 15-deoxyspergualin, on heterotopic rat heart transplantation, in comparison with cyclosporine. Transplantation 44: 483–487PubMedGoogle Scholar
  2. 2.
    Suzuki S, Kanashiro M, Amemiya H (1987) Immunosuppressive effect of a new drug, 15-deoxyspergualin, in heterotopic rat heart transplantation: in vivo energy metabolic studies by31P-NMR spectroscopy. Transplant Proc 19: 3982–3984PubMedGoogle Scholar
  3. 3.
    Suzuki S, Kanashiro M, Watanabe H, Amemiya H (1988) Therapeutic effect of 15-deoxyspergualin on acute graft rejection detected by31P nuclear magnetic resonance spectrography, and its effect on rat heart transplantation. Transplantation 46: 669–672PubMedGoogle Scholar
  4. 4.
    Suzuki S, Kanashiro M, Watanabe H, Sakakibara I, Amemiya H (1989) Effect of 15-deoxyspergualin on rejection detected by31P nuclear magnetic resonance spectroscopy and in vivo mechanism of action in rat heart transplantation. Transplant Proc 21: 1094–1095PubMedGoogle Scholar
  5. 5.
    Swada S, Suzuki G, Kawase Y, Takafu F (1987) Novel immunosuppressive agent, FK506. In vitro effects on the cloned T cell activation. J Immunol 139: 1797–1803PubMedGoogle Scholar
  6. 6.
    Kino T, Inamura N, Sakai F, Nakahara K, Goto T, Okuhara M, Kohsaka M, Aoki H, Ochiai T (1987) Effect of FK-506 on human mixed lymphocyte reaction in vitro. Transplant Proc 19: 36–39Google Scholar
  7. 7.
    Lim SML, Thiru S, White DJG (1987) Heterotopic heart transplantation in the rat receiving FK-506. Transplant Proc 19: 68–70Google Scholar
  8. 8.
    Murase N, Todo S, Lee PH, Lai HS, Chapman F, Nalesnik MA, Makowka L, Starzl TE (1987) Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc 19: 71–75Google Scholar
  9. 9.
    Todo S, Ueda J, Demetris JA, Imventarza M, Nalesnik M, Venkataramanan R, Makowka L, Starzl TE (1988) Immunosuppression of canine, monkey, and baboon allografts by FK506: with special reference to synergism with other drugs and tolerance induction. Surgery 104: 239–249PubMedGoogle Scholar
  10. 10.
    Thiru S, Collier DSJ, Caln R (1987) Pathological studies in canine and baboon renal allograft recipients immunosuppressed with FK506. Transplant Proc 19: 98–99Google Scholar
  11. 11.
    Nalesnik MA, Todo S, Murase N, Gryzan S, Lee PH, Makowka L, Starzl TE (1987) Toxicology of FK506 in the Lewis rat. Transplant Proc 19: 89–92PubMedGoogle Scholar
  12. 12.
    Ochiai T, Nakajima K, Nagata M, Hori S, Asano T, Isono K (1987) Studies of the induction and maintenance of long-term graft acceptance by treatment with FK506 in heterotopic cardiac allotransplantation in rats. Transplantation 44: 734–738PubMedGoogle Scholar
  13. 13.
    Brooks WM, Haseler LJ, Clarke K, Willis RJ (1986) Relation between the phosphocreatine to ATP ratio determined by31P nuclear magnetic resonance spectroscopy and left ventricular function in underperfused guinea-pig heart. J Mol Cell Cardiol 18: 149–155PubMedGoogle Scholar
  14. 14.
    Fraser CD, Chacko VP, Jacobus WE, Soulen RL, Hutching GM, Reitz BA, Baumgartner WA (1988) Metabolic changes preceding functional and morphologic indices of rejection in heterotopic cardiac allografts. Transplantation 46: 346–351PubMedGoogle Scholar
  15. 15.
    Salomon NW, Stinson EB, Griepp RB, Shumway NE (1978) Alterations in total and regional myocardial blood flow during acute rejection of orthotopic canine cardiac allografts. J Thorac Cardiovasc Surg 75: 542–547PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • Seiichi Suzuki
    • 1
  • Masaru Kanashiro
    • 2
  • Ryosuke Hayashi
    • 1
  • Takashi Kenmochi
    • 1
  • Toshiyuki Fukuoka
    • 1
  • Hiroshi Amemiya
    • 1
  1. 1.Department of Surgical ResearchNational Cardiovascular CenterSuita, OsakaJapan
  2. 2.Laboratory of Nuclear Magnetic Resonance, Research InstituteNational Cardiovascular CenterSuita, OsakaJapan

Personalised recommendations